Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive


Options:
A: Inclusion Criteria:

* Male or Female, 16 year or older
* Clinical diagnosis of focal epilepsy for at least 1 year
* History of poor response to at least 1 anti-epileptic drug in the past
* Current treatment with 1 or 2 anti-epileptic drugs
* Should have at least 3 seizures per month

Exclusion Criteria:

* Generalized epilepsy
* Cannot count your seizures
* Unstable medical disease, such as a recent heart attack or uncontrolled diabetes
* Major psychiatric illness
* Recent drug or alcohol abuse
* Unable to swallow pills
B: Inclusion Criteria:

1. Age 18-70 years old,
2. Diagnosis of epilepsy for at least 1 year,
3. Presenting, on average, at least 3 partial onset seizures per month,
4. Currently treated with a stable dose (i.e., for at least 4 weeks) of no more than 3 anti-epileptic drugs (AEDs),

Exclusion Criteria:

1. Have experienced status epilepticus in the past 3 months,
2. Have any serious diseases,
3. History of major psychiatric disorders within the past 2 years.
4. Have received an experimental drug/device within the past 30 days
5. Are pregnant or breastfeeding.
C: Inclusion Criteria:

* Patients must complete Visit 8 (Day 112) of the double-blind treatment phase of Study EPY-2003 to be eligible for entry into the open-label treatment phase of Study EPY-2006.

Exclusion Criteria:

* Patients who have seizures that cannot be quantitated accurately
* Patients with a history of nonepileptic seizures, serious systemic disease, progressive neurologic disorder, a major psychiatric disorder, status epilepticus in the past 3 months, vagal nerve stimulation discontinuation within the past 3 months
* Patients with a history of drug or alcohol abuse within the past 2 years
* Patients currently taking felbamate, vigabatrin, or tricyclic antidepressants
* and patients who are pregnant or nursing.
D: Inclusion Criteria:

* Diagnosis of partial onset seizures
* had a neuroimaging procedure (computed tomography \[CT\] or magnetic resonance imaging \[MRI\] within the past 5 years that excluded a progressive neurologic disorder
* History of inadequate response to at least 1 antiepileptic drug
* Current treatment with at least 1 and up to 3 antiepileptic drugs. To be eligible for the double-blind treatment phase of study CARISEPY3013, patients must: have at least 6 partial onset seizures during the 56-day baseline period
* Have not had \> = 100 partial onset seizures per 28 days in the baseline period
* And no seizure-free period of more than 3 weeks during the baseline period.

Exclusion Criteria:

* History of status epilepticus or epilepsia partialis continua in the 6 months before study entry
* Have a generalized epileptic syndrome
* have a diagnosis of Lennox-Gastaut Syndrome
* Currently experiencing seizures that cannot be counted accurately
* have experienced rates of \> = 100 partial onset seizures in any monthly period in the 6 months before study entry
* Have a history of any current or past nonepileptic seizures, including psychogenic seizures
* History of or current serious or medically unstable systemic disease
* evidence of cardiac disease, including unstable angina, myocardial infarction, within the past 2 years, uncontrolled heart failure, major arrhythmias, congenital short QT syndrome, or significant shortening or lengthening of the QTc interval of the electrocardiogram
* progressive neurologic disorder, such as a brain tumor, demyelinating disease, and degenerative CNS disease, or active CNS infection
* current or past (within the past year) major psychotic disorder
* History of suicidal or homicidal ideation within the past 2 years, or an episode of suicide attempt or homicide at any time in the past.

Answer: B